US House as­sem­bles bi­par­ti­san cau­cus on do­mes­tic phar­ma man­u­fac­tur­ing

The US House of Rep­re­sen­ta­tives is tak­ing a fur­ther in­ter­est in do­mes­tic phar­ma man­u­fac­tur­ing by cre­at­ing the Do­mes­tic Phar­ma­ceu­ti­cal Man­u­fac­tur­ing Cau­cus, led by Reps. Bud­dy Carter (R-GA), Elis­sa Slotkin (D-MI), Gus Bili­rakis (R-FL) and Chris­sy Houla­han (D-PA).

As the sup­ply chain in­creas­ing­ly is out­sourced to Chi­na and In­dia, par­tic­u­lar­ly on the ac­tive phar­ma­ceu­ti­cal in­gre­di­ent side, the cau­cus will aim to fo­cus on mov­ing for­ward leg­is­la­tion that in­cen­tivizes greater do­mes­tic man­u­fac­tur­ing of med­i­cines. Carter said the cau­cus will try to re­duce US re­liance on “for­eign ad­ver­saries,” try to en­sure an ad­e­quate sup­ply of phar­ma­ceu­ti­cals, and try to halt sup­ply chain dis­rup­tions.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN